' Chairman, Dr Peter Jonson, said that the Iliad acquisition is an important step towards Bionomics
' aspirations to significantly grow Bionomics
Mosquitoes, their bionomics
and relation to disease.
will acquire Neurofit for a total cost of Euro1.
holds patent applications at various stages of prosecution incorporating over 600 genes it has discovered and related utility in specific therapeutic and diagnostic applications.
Under the alliance, Bionomics
grants to GTG worldwide testing and marketing rights, including exclusivity for Australia and New Zealand, to new epilepsy tests developed by Bionomics
In 2005, Iliad was acquired by Bionomics
, which further accelerated progress with the program.
Rathjen commented, "We have already seen the United States launch of Bionomics
first epilepsy diagnostic test by Athena, only a month or so after signing the licensing agreement.
ADELAIDE, Australia, June 15, 2015 /PRNewswire/ -- Bionomics
Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system and cancer, announced today that it filed a patent application covering the use of BNC105 in combination with immune checkpoint inhibitors for the treatment of cancer.
of the potato tuber moth Phthorimaea operculella (Lepidoptera: Gelechiidae) at Pukekohe.
and Merck Serono to Collaborate to Discover and Develop Novel, Oral Treatment for MS
Limited (Australia) has strengthened its presence in the United States market.
MELBOURNE, Australia, April 20, 2015 /PRNewswire/ -- Bionomics
Limited (ASX: BNO, OTCQX: BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced the initiation of a Phase II clinical study of BNC210, the Company's drug candidate in development for the treatment of anxiety and depression.
and Taxonomy of the Euonymus Scale, Unaspis euonymi (Comstock), and Detailed Biological Information on the Scale in Maryland.
One of the first projects is to discover and develop compounds directed at BNO69, the CTx participant Adelaide-based Bionomics
Limited's own proprietary cancer target.
Limited (Adelaide, Australia) granted a licence to Boston-based Athena Diagnostics (Boston, MA) to market Bionomics
' childhood epilepsy diagnostic to neurologists in North America and Japan.